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Purpose: The purpose of our study was to validate diffusion-weighted MRI (DWI) 
before and after superparamagnetic iron oxide (SPIO) injection for assessment of 
hepatic metastases. Materials and Methods: Eighty-six hepatic metastases (size 
range, 0.3-4.7 cm; mean, 1.5 cm) verified pathologically or by follow-up imaging 
studies in 22 consecutive patients (17 men and 5 women; 44-83 years; mean age, 
60 years) during a 13-month period were enrolled. Hepatic MRI, including DWI 
(b-factors=50, 400, 800 s/mm2) with breath-holding technique of single-shot spin-
echo echo-planar imaging (TR/TE=1000/69 ms, average=2) before and after SPIO 
administration, were retrospectively reviewed by two independent radiologists with 
a 5-point scale confidence score for each hepatic lesion on pre-contrast DWI (pre-
DWI), SPIO-enhanced DWI (SPIO-DWI), and SPIO-enhanced T2*-weighted im-
aging (SPIO-T2*wI). Results: For all lesions, SPIO-T2*wI showed significantly 
higher confidence score in the diagnosis of hepatic metastases than pre-contrast or 
SPIO-DWI regardless of the size of b-factors (p<0.05) with only one exception; us-
ing b-factor=50 s/mm2, the score of SPIO-T2*wI was still higher than SPIO-DWI 
but there was no statistical significance given by observer 1 (p=0.730). For the sub-
centimeter lesions (n=37), SPIO-T2*wI showed the highest score, and using b-fac-
tor=50 or 400 s/mm2 SPIO-DWI showed similar confidence scores to SPIO-T2*wI 
by both observers (p>0.05). Pre-DWI using b-factor=50 sec/mm2 was also compa-
rable with SPIO-T2*wI by observer 1 (p=0.060). Conclusion: Pre-DWI has a lim-
ited value for the assessment of hepatic metastases, however, the repetition of DWI 
after SPIO injection using small b-factors could complement SPIO-T2*wI, espe-
cially for subcentimeter lesions.
Key Words:   Liver, metastasis, diffusion magnetic resonance imaging, superpara-
magnetic iron oxide (SPIO)
INTRODUCTION
For patients with extrahepatic malignancies, especially metastases from colorectal 
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for informed consent from individual patients. During a 
13-month period from March 2007 to March 2008, 299 
consecutive patients underwent hepatic MRI with DWI, 
gadolinium-enhanced dynamic imaging, and subsequent 
SPIO-enhanced MRI for the assessment of focal liver le-
sions in our institution. To be enrolled as subjects in this 
study, patients should have one or more metastatic lesions 
in the liver from extrahepatic malignancy and the lesions 
should be verified pathologically or by follow-up imaging 
studies. Electronically stored clinical records and imaging 
interpretation notes obtained from all 299 patients were re-
viewed by a study coordinator, and a total of 22 patients (17 
men and 5 women; 44-83 years; mean age, 60 years) were 
finally selected. Among 86 lesions found in the subjected 
patients. 21 lesions were confirmed by pathology from op-
eration or biopsy (n=21) or follow-up imaging studies (n=65). 
At follow-up imaging (range to 5 to 13 months), a lesion 
was deemed malignant if it showed 20% or greater in size. 
The primary cancer sites of these patients were as follows: 
13 colorectal cancers, 3 gastric cancers, 2 breast cancers, 2 
renal cell carcinomas, 1 pancreatic cancer, and 1 nasopha-
ryngeal cancer. There was only 1 lesion in nine patients, 2 
nodules in three patients, 3 nodules in one patient, 5 nod-
ules in three patients, and six patients had 6, 7, 8, 9, 10 or 
13 nodules in each patient. 
MRI techniques
MRI was performed using a 1.5-T system (Magnetom Avan-
to; Siemens, Erlangen, Germany) equipped with high-per-
formance gradients (maximum amplitude 45 mT/m) and a 
six-element phased-array surface coil.
The routine MRI protocol of our institute consisted of 
spectral fat suppression, T2-weighted, half-Fourier acquisi-
tion, single-shot turbo spin-echo images, T1-weighted dou-
ble-echo chemical shift gradient-echo (GRE) sequence, and 
dynamic contrast-enhanced imaging, using a 3D GRE se-
quence in the axial plane consisting of one pre-contrast se-
ries, followed by three successive post-contrast series (early 
arterial, late arterial, and portal phase imaging), and by 
5-min delayed phase imaging after administration of a bo-
lus injection of gadopentetate dimeglumine (0.1 mmol/kg 
of Magnevist; Bayer HealthCare, Berlin, Germany). After 
the completion of dynamic imaging, SPIO (8 µmol iron/kg 
of Resovist; Bayer HealthCare, Berlin, Germany) was intra-
venously injected as the second contrast agent for the SPIO-
enhanced T2-weighted imaging and T2*wI. After 10 min-
utes, free-breathing navigator-triggered T2wI was obtained 
cancer, it has been established that complete resection of 
these lesions is beneficial to the patient’s prognosis and sur-
vival, and imaging assessment of disease extent is crucial 
for treatment planning.1,2 Among the various imaging tech-
niques using computed tomography or magnetic resonance 
imaging (MRI), superparamagnetic iron oxide (SPIO)-en-
hanced MRI has been regarded as one of the most reliable 
methods for the detection of hepatic metastases.3 Utilizing 
recent advances in MR technology such as parallel imaging 
with the use of a phased-array multicoil, diffusion-weighted 
MRI (DWI) has been successfully applied in the assess-
ment of focal hepatic lesions.4,5
Recently, some researchers have suggested that hepatic 
metastases tend to show higher signal intensities on DWI 
compared with fast spin-echo T2-weighted imaging (T2wI), 
and DWI is superior to the conventional T2wI in the detec-
tion of hepatic metastases.6 Despite a previous investigation 
by Nasu, et al.,7 which showed that DWI is comparable to 
SPIO-enhanced T2wI in the assessment of hepatic metasta-
ses, there are several unsolved problems in the clinical ap-
plications of DWI for examining focal liver lesions.8 One 
problem is that some metastatic liver tumors are invisible 
on DWI due to apparent diffusion coefficient (ADC) values 
similar to that of normal liver parenchyma.9 Another is the 
difficulty of standardization of the optimal b-factors in dif-
ferent machines made by various venders. Thirdly, it is 
common to have image degradation due to inherent motion 
artifacts in the left lobe of the liver.
As for SPIO-enhanced MRI, there is a preliminary study 
with a limited number of patients that DWI performed after 
SPIO injection could improve the recognition of malignant 
focal lesions by increasing the lesion-to-liver contrast which 
depends on the signal drop of background parenchyma 
with normal phagocytic function of Kupffer cells after SPIO 
injection compared with conventional pre-contrast DWI 
(pre-DWI).10 The purpose of our present study was to vali-
date DWI with the use of various b-factors before and after 
SPIO injection for MRI assessment of hepatic metastases 





Approval for this study was obtained from the institutional 
review board at our hospital, which waived the requirement 
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Two observers (10 years and 2 years of experience in ab-
dominal imaging, respectively) independently reviewed sev-
en different imaging sets consisted of SPIO-T2*wI, three 
pre-DWI with different b-factors (50, 400, 800 s/mm2) and 
three SPIO-DWI with different b-factors (50, 400, 800 s/
mm2), and scored the individual arrow-indicated lesions ac-
cording to the 5-point confidence scale (1, no distinguish-
able abnormal signals from background parenchyma; 2, 
poorly defined abnormal signals but not well distinguished 
from background parenchyma; 3, poorly defined but well 
distinguished from background parenchyma; 4, well defined 
with marginal blurring; 5, well defined with sharp margin). 
Statistical analyses
According to the longest dimension, each lesion was cate-
gorized into one of the two groups (1 cm or greater, less 
than 1 cm) and separately analyzed. Lesion location was 
also divided into two categories (right versus left hepatic 
lobes) and separately analyzed. For convenience of statisti-
cal analysis, caudate lobe lesions were included in right 
lobe lesions in the present study. By using Wilcoxon signed 
rank test, the confidence scores of each lesion in pre-DWI 
vs. SPIO-DWI, pre-DWI vs. SPIO-T2* weighted images, 
and SPIO-DWI vs. SPIO-T2*-weighted images were com-
pared to each other. SPSS version 15.0 (SPSS Inc., Chica-
go, IL, USA) was used for statistical analysis, and a p value 
of less than 0.05 was considered statistically significant. In-
terobserver variability was assessed for lesion scoring (0.00-
0.20, indicated slight agreement; 0.21-0.40, fair agreement; 
0.41-0.60, moderate agreement; 0.61-0.80, substantial agree-





For all 86 lesions (0.3-4.7 cm; mean, 1.5 cm) studied, the 
mean confidence scores on each of the seven image sequenc-
es were calculated and compared with each other (Fig. 1). 
The mean confidence score of SPIO-T2*wI was always 
higher than those of pre-contrast or SPIO-DWI, regardless of 
the b-factors, as rated by the two observers; all mean confi-
dence score of SPIO-T2*wI was statistically significant 
(p<0.05), except SPIO-DWI using a b-factor of 50 s/mm2 
scored by observer 1 (p=0.730) (Table 1) (Fig. 2). Compared 
with pre-DWI, the mean confidence scores of SPIO-DWI 
were always higher using the same b-factors (p<0.05).
using turbo spin-echo sequence (TR 3000-6000 ms, TE 60 
ms, flip angle 150°, echo train length 13, bandwidth 260 
kHz, matrix 384×193, FOV 273×379 mm, slice thickness 6 
mm, interslice gap 1.2 mm, slices 30), followed by a breath-
hold 2D GRE sequence (TR 196 ms, TE 10 ms, flip angle 
30°, matrix 320×168, slice thickness 6 mm, interslice gap 
1.2 mm) for SPIO-T2*wI.
DWI was performed using a single-shot spin-echo echo-
planar imaging sequence that combined two diffusion (mo-
tion-probing) gradients before and after 180º pulse along all 
three directions - the section-select, phase-encoding, and fre-
quency-encoding directions - and data acquisition with an 
echo-planar imaging (EPI) readout by applying three differ-
ent b-factors of 50, 400, and 800 s/mm2. Other technical pa-
rameters were: TR 1000 ms, TE 69 ms, matrix 128×192, 
FOV 308×379 mm, slices 27 (9 slices for each b-factor), 
thickness 6 mm, interslice gap 30%, average 2, bandwidth 
1735 Hz/pixel, and acquisition time 22 s. Parallel imaging 
algorithms (GRAPPA) with an acceleration factor of 2 were 
added to reduce acquisition time. Spectral fat saturation was 
employed systematically to suppress chemical-shift artifacts. 
The sequence was obtained within a single breath-holding 
period for upper half of the liver and another single breath-
holding period for lower half of the liver, and a total of 18 
slices were acquired for each b-factor. Two different DWI 
sets (pre- and post-SPIO) were obtained with the same im-
aging parameters. Pre-DWI was performed before the dy-
namic imaging, and SPIO-enhanced DWI (SPIO-DWI) was 
performed just before the acquisition of SPIO-enhanced T2 
and T2*wI. All scans were sent to picture archiving and 
communication system (PACS) for interpretation on PACS 
workstations.
Image analyses 
For the lesions studied, lesion localization and size mea-
surements were performed by the study coordinator using 
electronic arrows and calipers on various images. The elec-
tronic arrows were digitally saved, and the location and size 
of each lesion were recorded on a data sheet with the image 
number for the future analyses. Pre-contrast T1-weighted 
spoiled GRE images were used for the localization and size 
measurement of each lesion if possible. The SPIO-enhanced 
T2wI or the portal phase images of dynamic 3D GRE were 
secondarily or thirdly used for the same purpose. For the le-
sions exclusively defined on the SPIO-T2*wI (n=2) or SPIO-
DWI (n=6), localization and size measurements were per-
formed on those images alone.
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es except SPIO-DWI using a b-factor of 50 s/mm2 (observer 
1, p=0.200; observer 2, p=0.430) (Fig. 3). When the confi-
dence scores were compared to each other between the pre-
contrast and SPIO-DWI with corresponding b-factors, SPIO-
DWI always showed higher scores regardless of the different 
For the lesions greater than or equal to 1 cm (n=49), the 
mean confidence score of SPIO-T2*wI was always higher 
than those of pre- or SPIO-DWI irrespective of the different 
b-factors; all mean confidence scores of SPIO-T2*wI were 
statistically significantly higher (p<0.05) than other sequenc-
Table 1. Comparison of Mean Confidence Scores according to Lesion Size on Seven Different Sequences
b-factor (s/mm2)
Overall (n=86) ≥1 cm (n=49) <1 cm (n=37)
Observer 1 Observer 2 Observer 1 Observer 2 Observer 1 Observer 2
SPIO-T2*wI vs. pre-DWI
    50
> > > > > >
p<0.001 p=0.001 p<0.001 p=0.012   p=0.060* p=0.021
    400
> > > > > >
p=0.003 p=0.013 p=0.002 p=0.046 p=0.021 p=0.049
    800
> > > > > >
p<0.001 p=0.015 p=0.034 p=0.031 p=0.037 p=0.021
SPIO-T2*wI vs. SPIO-DWI
    50
> > > > > >
  p=0.730* p<0.001   p=0.200*   p=0.430*   p=0.680*   p=0.070*
    400
> > > > > >
p<0.001 p<0.001 p<0.001 p=0.012   p=0.350*   p=0.610*
    800
> > > > > >
p=0.001 p=0.015 p=0.003 p=0.048 p=0.049 p=0.029
Pre-DWI vs. SPIO-DWI†
    50
< < < < < <
p=0.001 p=0.011 p=0.002 p=0.040 p=0.045 p=0.036
    400
< < < < < <
p<0.001 p=0.006 p=0.002 p=0.032 p=0.023 p=0.039
    800
< < < < < <
p<0.001 p=0.008 p=0.001 p=0.041 p=0.045 p=0.035
T2*wI, T2*-weighted imaging; DWI, diffusion-weighted MR imaging; SPIO, superparamagnetic iron oxide.
The direction of inequality signs means the relative superiority between two sequences in comparison for the mean confidence score accompanied with p 
values.
*A p value >0.05 was not considered statistically significant.
†For comparison of pre-DWI with SPIO-DWI, only the corresponding sequence images using same b-factor were compared each other.  
Fig. 1. Mean confidence scores with standard deviations of each MRI sequence for overall lesions. SPIO-T2*wI, SPIO-enhanced T2*wI; 
Pre-DWI_50, pre-contrast DWI with a b-factor of 50 s/mm2; pre-DWI_400, pre-contrast DWI with a b-factor of 400 s/mm2; pre-DWI_800, 
pre-contrast DWI with a b-factor of 800 s/mm2; SPIO-DWI_50, SPIO-enhanced DWI with a b-factor of 50 s/mm2; SPIO-DWI_400, SPIO-
enhanced DWI with a b-factor of 400 s/mm2; SPIO-DWI_800, SPIO-enhanced DWI with a b-factor of 800 s/mm2. SPIO, superparamagnetic 
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1.3±1.0 cm) in the right hepatic lobe including two caudate 
lobe lesions and 28 lesions (mean size±standard deviation, 
1.9±1.3 cm) in the left hepatic lobe. Even in the left hepatic 
lobe lesions, SPIO-T2*wI had highest confidence score 
compared with pre-DWI or SPIO-DWI in most cases ex-
cept for the comparison with SPIO-DWI by observer 1 who 
showed higher confidence score of SPIO-DWI with (b-fac-
tors of 50 s/mm2, p<0.001) or without statistical signifi-
cance (b-factors of 400 s/mm2, p=1.000) (Table 2). Like the 
right lobe lesions, left lobe lesions also showed the superi-
ority of SPIO-DWI compared to pre-DWI with (all b-fac-
tors by observer 1 and b-factor of 50 s/mm2 by observer 2, 
b-factors (p<0.05). 
For lesions less than 1 cm (n=37), SPIO-T2*wI showed 
the highest mean qualitative score and SPIO-DWI (b-fac-
tors of 50 and 400 s/mm2) showed confidence scores simi-
lar to SPIO-T2*wI (observer 1, p=0.680 and 0.350, respec-
tively; observer 2, p=0.070 and 0.610, respectively). Pre-
DWI using a b-factor of 50 s/mm2 was also comparable with 
SPIO-T2*wI as rated by observer 1 (p=0.060). Compared 
with pre-DWI, the mean confidence scores of SPIO-DWI us-
ing the corresponding b-factors were always greater, even for 
the subcentimeter lesions (p<0.05) (Figs. 4, 5 and 6). 
There were 58 lesions (mean size±standard deviation, 
Fig. 3. Mean confidence scores with standard deviations of each MRI sequence for 1 cm or larger lesions. SPIO-T2*wI, SPIO-enhanced 
T2*wI; Pre-DWI_50, pre-contrast DWI with a b-factor of 50 s/mm2; pre-DWI_400, pre-contrast DWI with a b-factor of 400 s/mm2; pre-
DWI_800, pre-contrast DWI with a b-factor of 800 s/mm2; SPIO-DWI_50, SPIO-enhanced DWI with a b-factor of 50 s/mm2; SPIO-DWI_400, 
SPIO-enhanced DWI with a b-factor of 400 s/mm2; SPIO-DWI_800, SPIO-enhanced DWI with a b-factor of 800 s/mm2. SPIO, superpara-
magnetic iron oxide; DWI, diffusion-weighted MRI; MRI, magnetic resonance imaging; T2*wI, T2* weighted imaging.
Fig. 2. A 48-year-old man with sigmoid colon cancer. SPIO-enhanced T2*-weighted image (A) shows a metastatic lesion (arrow) in the 
lateral segment. On the pre-contrast DWIs using b-factor (s/mm2) of 50 (B), 400 (C) and 800 (D), relative signal intensities of the lesions are 
gradually decreased with the increase of b-factors. On the SPIO-enhanced DWIs using b-factor (s/mm2) of 50 (E), 400 (F) and 800 (G), the 
lesions are more conspicuously seen, especially on the images using smaller b-factors. With an increase of b-factors, marginal blurring 
of the lesion looks more severe. SPIO, superparamagnetic iron oxide; DWI, diffusion-weighted MRI.
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DISCUSSION
When dealing with contrast-enhanced hepatic MRI, SPIO 
reduces the signal intensity of normal liver parenchyma in a 
manner dependent on the phagocytic effect of Kupffer cells, 
resulting in an increase of lesion-to-liver contrast in cases of 
hepatic malignancy and, therefore, SPIO-enhanced MRI has 
been thought to be one of the best imaging tools in the as-
sessment of hepatic metastases.11-13 DWI creates image con-
p<0.05) or without statistical significance (b-factors of 400 
and 800 s/mm2 by observer 2, p>0.3) (Table 2).
The linear-weighted kappa values for interobserver agree-
ment in the confidence scoring showed moderate or sub-
stantial agreements for all MRI sequences (SPIO-T2*wI, 
0.50; SPIO-DWI with a b-factor of 50 s/mm2, 0.47; SPIO-
DWI with a b-factor of 400 s/mm2, 0.51; SPIO-DWI with a 
b-factor of 800 s/mm2, 0.52; pre-DWI with a b-factor of 50 s/
mm2, 0.63; pre-DWI with a b-factor of 400 s/mm2, 0.55; pre-
DWI using a b-factor of 800 s/mm2, 0.52). 
Fig. 4. Mean confidence scores with standard deviations of each MRI sequence for lesions smaller than 1 cm. SPIO-T2*wI, SPIO-
enhanced T2*wI; Pre-DWI_50, pre-contrast DWI with a b-factor of 50 s/mm2; pre-DWI_400, pre-contrast DWI with a b-factor of 400 s/
mm2; pre-DWI_800, pre-contrast DWI with a b-factor of 800 s/mm2; SPIO-DWI_50, SPIO-enhanced DWI with a b-factor of 50 s/mm2; SPIO-
DWI_400, SPIO-enhanced DWI with a b-factor of 400 s/mm2; SPIO-DWI_800, SPIO-enhanced DWI with a b-factor of 800 s/mm2. SPIO, su-
perparamagnetic iron oxide; DWI, diffusion-weighted MRI; MRI, magnetic resonance imaging; T2*wI, T2* weighted imaging.
Fig. 5. A 69-year-old man with colon cancer and numerous metastases throughout the liver including the largest one in the left hemiliver. 
On the SPIO-enhanced T2*-weighted image (A), metastatic lesions are not well distinguished from the background liver due to small le-
sion size and masking effect of the intrahepatic vasculature with high signal intensity. On the pre-contrast DWIs using b-factor (s/mm2) of 
50 (B), at least 5 metastases (arrowheads) in a single level of right hemiliver are well delineated from the background liver due to ‘black-
blood’ effect. The confidence is worsened on the images using higher b-factors of 400 (C) or 800 (D) with low signal intensity and margin-
al blurring of the lesions. On the SPIO-enhanced DWIs using b-factor (s/mm2) of 50 (E) or 400 (F), all five lesions are conspicuously seen, 
compared with poor marginal definition on the image using the b-factor of 800 (G). Compared with pre-contrast DWI, SPIO-enhanced 
DWI using corresponding b-factors shows consistently higher lesion-to-liver contrasts. SPIO, superparamagnetic iron oxide; DWI, diffu-
sion-weighted MRI.
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Table 2. Comparison of Mean Confidence Scores according to Lesion Location on Seven Different Sequences
b-factor (s/mm2)
Right lobe (n= 58)† Left lobe (n=28)
Observer 1 Observer 2 Observer 1 Observer 2
SPIO-T2*wI vs. pre-DWI
    50
> > > >
p=0.002 p<0.001 p=0.029 p=0.004
    400
> > > >
p<0.001 p<0.001 p=0.002 p=0.002
    800
> > > >
p<0.001 p<0.001 p<0.001 p<0.001
SPIO-T2*wI vs. SPIO-DWI
    50
> > < >
  p=0.083* p<0.001 p=0.005 p=0.033
    400
> > < >
p=0.013 p<0.001   p=1.000* p=0.003
    800
> > > >
p<0.001 p<0.001 p=0.016 p<0.001
Pre-DWI vs. SPIO-DWI‡
    50
< < < <
  p=0.053*   p=0.445* p<0.001 p=0.049
    400
< < < <
p=0.005 p=0.002 p=0.004   p=0.373*
    800
< < < <
p=0.003 p=0.005 p=0.006   p=0.308*
T2*wI, T2*-weighted imaging; DWI, diffusion-weighted MR imaging; SPIO, superparamagnetic iron oxide.
The direction of inequality signs means the relative superiority between two sequences in comparison for the mean confidence score accompanied with p 
values.
*A p value >0.05 was not considered statistically significant.
†Including two caudate lobe lesions.
‡For comparison of pre-DWI with SPIO-DWI, only the corresponding sequence images using same b-factor were compared each other.
Fig. 6. A 69-year-old man with multiple hepatic metastases in the left hemiliver. A small metastatatic lesion (arrowhead) on SPIO-
enhanced T2*-weighted image (A) is not well distinguished from the background liver due to small size and the masking effect of the in-
trahepatic vasculature. On the pre-contrast DWIs using b-factor (s/mm2) of 50 (B), 400 (C) and 800 (D), there is severe motion artifact and 
no focal lesion is defined. On the SPIO-enhanced DWIs using b-factor (s/mm2) of 50 (E), 400 (F) and 800 (G), the lesion (arrowhead) is well 
delineated due to the increased lesion-to-liver contrast in spite of the motion artifact. SPIO, superparamagnetic iron oxide; DWI, diffu-
sion-weighted MRI.
A B C D
E F G
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with the SPIO-T2*wI in the present study. In a recent study 
by Coenegrachts, et al.16 comparing SPIO-enhanced T2wI 
with pre-contrast and SPIO-DWI for various benign and ma-
lignant lesions, lesion visibility of hepatic metastases from 
colorectal cancers was comparable between the pre-contrast 
and SPIO-DWI because of increased lesion-to-liver contrast 
after injection of SPIO despite degradation of overall image 
quality due to the size of the b-factors. In the present study, 
the inferiority of pre-DWI might be related to inhomogeneous 
group of extrahepatic primary lesion sites, which could be 
less conspicuous on the precontrast T2wI or DWI using a 
small b-factor than with the SPIO-enhanced images.
For smaller (<1 cm) lesions, however, pre-DWI with a 
low b-factor (50 s/mm2) in addition to the SPIO-DWI with 
relatively low b-factors (50 and 400 s/mm2) showed quality 
scores comparable to SPIO-T2*wI in the present study. Due 
to the fact that small lesions can be obscured by vascular 
structures on SPIO-T2*wI, pre-DWI could possess a com-
parable ability in the detection of small lesions despite the 
inherent limitations mentioned above (Fig. 4). For SPIO-
DWI in the detection of subcentimeter lesions, Kiryu, et al.17 
also concluded that SPIO-DWI is able to recognize subcen-
timeter hepatic metastases because of suppression effect of 
vascular signals, masking the small lesions on SPIO-en-
hanced T2wI. Even though the previous study by Kiryu, et 
al.17 used the PROPELLER T2 fast spin echo sequence in-
stead of the spin-echo EPI used in the present study, our re-
sults are similar to theirs. Although not analyzed in this study, 
the quality of SPIO-DWI can also be limited by increased 
blooming effect, the susceptibility artifact from iron parti-
cles, which is worsened by increasing the b-factors.18 De-
spite diminution in the size of lesions by the blooming ef-
fect, however, the b-factor of 400 s/mm2 showed comparable 
confidence scores with increased lesion-to-liver contrast of 
T2*wI after SPIO injection.
This study has several limitations. First of all, due to retro-
spective nature of this study, pathologic proof was not possi-
ble for all lesions. Secondly, this study focused on the com-
parative conspicuity of each metastatic lesion from various 
primary malignancies on the imaging sequences studied, 
and the sensitivity or the specificity of each sequence was 
not calculated. Thirdly, there was a high potential of unpre-
dictable image degradation for the left lobe lesions related to 
pulsation artifacts.7 However, even in the left hepatic lobe 
lesions, the mean confidence score of SPIO-DWI was sig-
nificantly higher than pre-DWI, especially on the images, 
using small b-factor in the present study. Fourthly, according 
trast by the difference in the random, thermally-agitated dif-
fusion of water molecules in different tissues and has recently 
been included in the routine protocol of hepatic MRI with 
recent technical advances in reducing image distortion and 
increasing the signal-to-noise ratio.14
According to some recent investigations, DWI provids 
better sensitivity and comparable ability of lesion character-
ization, compared to the conventional breath-hold T2wI, in 
the assessment of focal hepatic lesions.6 In a comparative 
study between SPIO-enhanced imaging and DWI, Nasu, et 
al.7 showed that the combined interpretation of DWI, fast 
T2wI, and dual-echo gradient T1-weighted images yielded 
better accuracy than SPIO-enhanced T2wI in the evaluation 
of hepatic metastases, and suggested the potential of DWI to 
replace SPIO-enhanced T2wI in the preoperative evaluation 
of hepatic metastases.
Meanwhile, Naganawa, et al.10 applied DWI along with 
high b-factors (600 and 1000 s/mm2) before and after the ad-
ministration of SPIO during hepatic MRI for the assessment 
of focal liver lesions in 5 patients with hepatic metastases, 
and concluded that SPIO-DWI could enhance the recogni-
tion of hepatic metastases. In their study, the number of le-
sions detected on SPIO-DWI was larger than other imaging 
sequences including SPIO-T2, T2* and pre-DWI, however, 
none of the lesions was verified pathologically or by follow-
up studies.10 In the present study, we attempted to explore 
whether pre-DWI would be sufficient to replace SPIO-T2*wI 
and whether SPIO-DWI would be helpful in improving the 
lesion-to-liver contrast, depending on the lesion size and 
various b-factors that are available, with the use of a number 
of verified lesions of hepatic metastases.
In the present study, SPIO-T2*wI showed significantly 
better confidence scores than pre-DWI, regardless of the le-
sion size or the different b-factors, and only SPIO-DWI 
showed comparable confidence levels when the small b-fac-
tor (50 s/mm2) was used. Based on the present results, pre-
DWI would not be sufficient to replace SPIO-T2*wI due to 
limited spatial resolution and image artifacts in addition to 
inherently unpredictable lesion-to-liver contrast of various 
hepatic metastases. With smaller b-factors, diffusion effect is 
not so distinctively reflected on the images, especially for 
the solid lesions, and the imaging characteristics of DWI 
were similar to those of T2wI except for the black blood ef-
fect.15 In this situation, injection of SPIO would increase the 
lesion-to-liver contrast in DWI for some lesions which could 
be missed on T2wI or DWI with low b-factors, resulting in 
the increase of lesion conspicuity that would be comparable 
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S, et al. Hepatic metastases: diffusion-weighted sensitivity-encod-
ing versus SPIO-enhanced MR imaging. Radiology 2006;239: 
122-30.
8. Müller MF, Prasad PV, Siewert B, Edelman RR. [The in-vivo dif-
fusion measurements of the liver, kidneys, spleen and m. erector 
with an echo-planar imaging system in normal subjects]. Rofo 
1994;161:233-6.
9. Ichikawa T, Haradome H, Hachiya J, Nitatori T, Araki T. Diffu-
sion-weighted MR imaging with a single-shot echoplanar se-
quence: detection and characterization of focal hepatic lesions. 
AJR Am J Roentgenol 1998;170:397-402.
10. Naganawa S, Sato C, Nakamura T, Kumada H, Ishigaki T, Miura 
S, et al. Diffusion-weighted images of the liver: comparison of tu-
mor detection before and after contrast enhancement with super-
paramagnetic iron oxide. J Magn Reson Imaging 2005;21:836-40.
11. Senéterre E, Taourel P, Bouvier Y, Pradel J, Van Beers B, Daures 
JP, et al. Detection of hepatic metastases: ferumoxides-enhanced 
MR imaging versus unenhanced MR imaging and CT during arte-
rial portography. Radiology 1996;200:785-92.
12. Vogl TJ, Schwarz W, Blume S, Pietsch M, Shamsi K, Franz M, et 
al. Preoperative evaluation of malignant liver tumors: comparison 
of unenhanced and SPIO (Resovist)-enhanced MR imaging with 
biphasic CTAP and intraoperative US. Eur Radiol 2003;13:262-72.
13. Strotzer M, Gmeinwieser J, Schmidt J, Fellner C, Seitz J, Albrich 
H, et al. Diagnosis of liver metastases from colorectal adenocarci-
noma. Comparison of spiral-CTAP combined with intravenous 
contrast-enhanced spiral-CT and SPIO-enhanced MR combined 
with plain MR imaging. Acta Radiol 1997;38:986-92.
14. Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. 
Radiology 2010;254:47-66.
15. Hussain SM, De Becker J, Hop WC, Dwarkasing S, Wielopolski 
PA. Can a single-shot black-blood T2-weighted spin-echo echo-
planar imaging sequence with sensitivity encoding replace the re-
spiratory-triggered turbo spin-echo sequence for the liver? An op-
timization and feasibility study. J Magn Reson Imaging 2005;21: 
219-29.
16. Coenegrachts K, Matos C, ter Beek L, Metens T, Haspeslagh M, 
Bipat S, et al. Focal liver lesion detection and characterization: 
comparison of non-contrast enhanced and SPIO-enhanced diffu-
sion-weighted single-shot spin echo echo planar and turbo spin 
echo T2-weighted imaging. Eur J Radiol 2009;72:432-9.
17. Kiryu S, Watanabe M, Kabasawa H, Akahane M, Aoki S, Ohtomo 
K. Evaluation of super paramagnetic iron oxide-enhanced diffu-
sion-weighted PROPELLER T2-fast spin echo magnetic reso-
nance imaging: preliminary experience. J Comput Assist Tomogr 
2006;30:197-200.
18. Liang L, Korogi Y, Sugahara T, Shigematsu Y, Okuda T, Ikushima I, 
et al. Detection of intracranial hemorrhage with susceptibility-weight-
ed MR sequences. AJNR Am J Neuroradiol 1999;20:1527-34.
to inherent limitation of breath-holding technique for DWI, 
the number of excitation was limited and TR was too short 
to avoid T1 effect, thus resulting in lowering the signal-to-
noise ratio and lesion conspicuity, especially on pre-DWI. 
Increasing the number of excitation and lengthening of TR 
would improve the quality of pre-DWI by using free-breath-
ing data acquisition techniques which was not performed 
during our study period. Lastly, due to limited number of pa-
tients, separate analysis according to the nature of primary 
extrahepatic lesions was not possible and ADC value was 
not measured for each lesion. 
In conclusion, compared with SPIO-T2*wI, pre-DWI 
could not reach a comparable confidence score for the de-
tection of hepatic lesions, except subcentimeter lesions, on 
pre-DWI with a small b-factor (50 s/mm2). Despite the limi-
tations mentioned above, using breath-holding technique, 
pre-DWI is insufficient to replace SPIO-enhanced imaging 
for hepatic metastases from various primary origins. De-
pending on the increased confidence score, additional DWI 
after SPIO injection could complement SPIO-T2*wI in the 
assessment of small hepatic metastases.
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